Neuro-Oncology News

HemOnc Today and Healio.com/HemOnc will provide live coverage of the Chemotherapy Foundation Symposium, which will be held Nov. 8-10 in New York.

Nearly 2 years after former Vice President Joe Biden unveiled the cancer moonshot initiative, The Lancet Oncology Commission has detailed a roadmap to deliver on the recommendations of the moonshot’s blue ribbon panel.

The FDA approved IV rolapitant in combination with other antiemetic agents to prevent delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy for adults.

Oncology leaders who participated in an American Association for Cancer Research webinar this afternoon highlighted several advances in cancer research and emphasized the importance of robust medical research funding.

Howard A. Fine, MD, received a 5-year, $6 million NIH Director’s Pioneer Award for brain cancer research.

NIH launched the Partnership for Accelerating Cancer Therapies, a 5-year public-private research collaboration.

Patients with a higher number of DNA alterations detected by a liquid biopsy appeared more likely to respond to immune checkpoint inhibitors, according to retrospective study results published in Clinical Cancer Research.

ASCO and Friends of Cancer Research today released recommendations to broaden eligibility criteria for cancer clinical trials.

In this guest commentary, Marcela V. Maus, MD, PhD, assistant professor of medicine at Harvard Medical School and director of cellular immunotherapy at Massachusetts General Hospital Cancer Center, discusses early research regarding the use of chimeric antigen receptor (CAR) T-cell therapy for the treatment of glioblastoma following the approval of tisagenlecleucel -T suspension ( Kymriah , Novartis), the first CAR T - cell therapy approved in the United States.

Mike Schmidt, a Major League Baseball Hall of Famer who played 17 seasons with the Philadelphia Phillies, received a stage III melanoma diagnosis in 2013.